Pharmacokinetics of dibekacin in children with cystic fibrosis.
Dosages and pharmacokinetics of dibekacin were studied in a group of 15 children with cystic fibrosis (CF) and a control group of 9 children. The mean dosage regimens of dibekacin were respectively equal to 2.19 mg/kg and 2.16 mg/kg in the CF and non-CF patients. The mean peak serum values for the CF and non-CF groups were respectively equal to 5.3 micrograms/ml. Comparison of pharmacokinetic parameters (i.e. half-life, distribution volume, total body clearance and area under the curve) showed no significant difference between the two groups (p greater than 0.05).
D001219:Aspartate Aminotransferases / Q000097:blood; D002648:Child; D003404:Creatinine / Q000097:blood; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000378:metabolism*; D003982:Dibekacin / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D007700:Kinetics; D013997:Time Factors
D003982:Dibekacin; D007612:Kanamycin; D003404:Creatinine; D001219:Aspartate Aminotransferases